Form 4: 4D Molecular Therapeutics Director John F. Milligan Reports Stock Option Grant
SEC Form 4 Filing
Director John F. Milligan reports the acquisition of stock options in 4D Molecular Therapeutics.
Summary
- On May 21, 2024, John F. Milligan, a director of 4D Molecular Therapeutics, Inc. (FDMT), was granted stock options to purchase 26,791 shares of common stock at an exercise price of $25.15 per share.
- The options vest in three annual installments starting May 21, 2025, and fully vest by May 21, 2027, contingent upon continued service.
- Full vesting also occurs upon a Change in Control event as defined in the 2020 Incentive Award Plan.
- Following the transaction, Milligan directly holds options for 26,791 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and aligns the director's interests with shareholders. There are no explicit negative implications.
Positives
- The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
- The vesting schedule encourages long-term commitment from the director.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
- The vesting schedule of three years is typical for such grants, aligning with industry norms for incentivizing long-term performance.
- Comparable companies such as CRISPR Therapeutics and Editas Medicine also utilize stock options as part of their director compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
- The director is incentivized to contribute to the company's growth and profitability.
Key Dates
| Date | Description |
|---|---|
| 05/21/2024 | Date of stock option grant |
| 05/21/2025 | First vesting date for 1/3 of the stock options |
| 05/21/2027 | Final vesting date for the stock options |
| 05/20/2034 | Expiration date of the stock options |
| 05/23/2024 | Date of the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.